Uses of NOGO-A inhibitors and related methods

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8828390
APP PUB NO 20130136737A1
SERIAL NO

13809224

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention is directed to Nogo-A antagonists useful for the control of blood glucose or blood insulin levels in a subject and related use and formulation thereof. In particular, the invention is directed to Nogo-A antagonists useful for the prevention, repression or treatment insulin secretion deficiency and related methods and pharmaceutical formulations. In particular, the invention relates to Nogo-A antagonists useful in the treatment of diabetes mellitus.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • UNIVERSITE DE GENEVE;UNIVERSITAT ZURICH

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bonal, Claire Cambridge, US 1 39
Herrera, Pedro L Chene-Bourg, CH 2 39
Lalive, D'epinay Patrice Chene-Bougeries, CH 1 39
Pot, Kreis Caroline Geneva, CH 1 39
Schwab, Martin E Zurich, CH 17 125

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 9, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00